Similar to this, the addition of panitumumab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb), to chemotherapy with leucovorin, 5-fluorouracil, and oxaliplatin (FOLFOX) can significantly benefit patients with RAS-wild left-sided metastatic colorectal cancer compared with FOLFOX alone. This evidence concerns the gene EGFR and metastatic colorectal cancer.